Chemotherapy Archives - Page 3 of 18 - Cancer Therapy Advisor

Intermediate-dose cytarabine has demonstrated high efficacy as a chemomobilization agent.

Breast Cancer

Full Chemo Doses May Improve Survival in Breast Cancer

September 13, 2019

Maintaining full doses of chemo especially important early in the treatment course.

Multiple Myeloma

Nelfinavir Plus Lenalidomide, Dexamethasone Improves Response in Lenalidomide-Refractory Multiple Myeloma

By

Vicki Moore, PhD

September 13, 2019

Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.

It may be time for clinicians to re-evaluate the use of anagrelide in patients with high-risk ET.

IASLC/WCLC 2019

Using “Real-World” Data to Evaluate the Comparative Effectiveness and Safety of First-Line Chemotherapy Regimens in the Setting of Advanced NSCLC

By

Susan Moench, PhD, PA-C

September 5, 2019

There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.

Oral S-1 with cisplatin may not be inferior compared to docetaxel with cisplatin in advanced NSCLC.

IASLC/WCLC 2019

Factors Underlying Ethnic Differences in Treatment Toxicity and Response in Advanced NSCLC: A Review

By

Susan Moench, PhD, PA-C

September 5, 2019

There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.

Increasing genetic complexity over time allows multiple myeloma to acquire drug resistance, but immu

Hematologic Cancers

Single-Agent Ibrutinib Versus Rituximab-Based Chemoimmunotherapy in Waldenström Macroglobulinemia

By

Susan Moench, PhD, PA-C

August 13, 2019

No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.

Patients who slept poorly exhibited greater symptom burden and overall mood disturbance.

Multiple Myeloma

Switching to VTD During Chemotherapy Found to Be Linked to Better Outcomes in Older Patients

By

Susan Moench, PhD, PA-C

July 23, 2019

Elderly patients with myeloma who switched to bortezomib, thalidomide, and dexamethasone during frontline chemotherapy had better survival outcomes.

This fact sheet provides an overview of the underlying mechanisms, incidence, symptoms, and treatment of infusion-related reactions.

Gastrointestinal Cancers

Comparing Long-Course Chemoradiation With Short-Course Radiation Therapy in Rectal Cancer

By

Susan Moench, PhD, PA-C

July 2, 2019

Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.

Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic c

Pancreatic Cancer

ASCO Guideline Update: Modified FOLFIRINOX Is Preferred as Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma

By

Susan Moench, PhD, PA-C

June 18, 2019

The rate of grade 3/4 adverse events was higher for patients with resected pancreatic adenocarcinoma treated with adjuvant mFOLFIRINOX versus gemcitabine.